---
title: "Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer: Indication questions"
description: "Indication questions on Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Testing. Questions: What is Enhertu approved for in HER2-low breast cancer? How are patients selected for Enhertu in HER2-low breast cancer? What does HER2-ultralow mean for Enhertu eligibility? How do pathologists test for HER2-ultralow status for Enhertu? 1 further question follow. 5 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/indication"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer: Indication questions

Manufacturer: Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP  
Prescribing information: [Enhertu](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true)

Indication questions that apply to every indication of Enhertu are on [Enhertu (fam-trastuzumab deruxtecan-nxki), all indications: Indication](https://www.evicenter.com/medical-information/enhertu/indication).

## Indication

<a id="enhertu-indication"></a>

### What is Enhertu approved for in HER2-low breast cancer?

> “ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for:”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=ENHERTU%20is%20a%20HER2%2Ddirected%20antibody%20and%20topoisomerase%20inhibitor%20conjugate%20indicated%20for%3A)

> “HER2-Low and HER2-Ultralow Metastatic Breast Cancer
> As monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting
> As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy”

Source: [ENHERTU: ENHERTU® (fam-trastuzumab deruxtecan-nxki) | HER2-low and HER2-ultralow Breast HCP Site, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast#:~:text=conjugate%20indicated%20for%3A-,HER2%2DLow%20and%20HER2%2DUltralow%20Metastatic%20Breast%20Cancer,months%20of%20completing%20adjuvant%20chemotherapy)

## Testing

<a id="enhertu-her2-test-selection"></a>

### How are patients selected for Enhertu in HER2-low breast cancer?

> “Select patients for treatment with ENHERTU based on HER2 expression that is either HER2-low (IHC 1+ or IHC 2+/ISH–) or HER2-ultralow (IHC 0 with membrane staining).”

Source: [ENHERTU: Dosage, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/dosage#:~:text=Select%20patients%20for%20treatment%20with%20ENHERTU%20based%20on%20HER2%20expression,%28IHC%200%20with%20membrane%20staining%29.)

On the page, select: HER2-low or HER2-ultralow unresectable or metastatic breast cancer

> “Information on FDA-authorized tests for the detection of HER2 protein expression, HER2 gene amplification, and activating HER2 mutations is available at http://www.fda.gov/CompanionDiagnostics”

Source: [ENHERTU: Dosage, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/dosage#:~:text=Information%20on%20FDA%2Dauthorized%20tests%20for,mutations%20is%20available%20at%20http%3A%2F%2Fwww.fda.gov%2FCompanionDiagnostics)

Note: The indication requires HER2-low or HER2-ultralow status as determined by an FDA-authorized test.

<a id="enhertu-her2-ultralow-definition"></a>

### What does HER2-ultralow mean for Enhertu eligibility?

> “HER2-ultralow (IHC 0 with membrane staining) expression 
> as determined by Ventana’s PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal 
> Primary Antibody assay and evaluated at a central laboratory. HER2-ultralow is 
> defined as membrane staining that is seen in >0 and ≤10% of tumor cells.”

Source: [ENHERTU: Prescribing information, page 21, captured 2026-11-13](https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true#page=21)

> “Select patients for treatment with ENHERTU based on HER2 expression that is either HER2-low (IHC 1+ or IHC 2+/ISH–) or HER2-ultralow (IHC 0 with membrane staining).”

Source: [ENHERTU: Dosage, captured 2026-11-13](https://www.enhertuhcp.com/en/dosing/dosage#:~:text=Select%20patients%20for%20treatment%20with%20ENHERTU%20based%20on%20HER2%20expression,%28IHC%200%20with%20membrane%20staining%29.)

On the page, select: HER2-low or HER2-ultralow unresectable or metastatic breast cancer

Note: The first passage is from the DESTINY-Breast06 description in section 14.3 of the Prescribing Information.

<a id="enhertu-her2-ultralow-test"></a>

### How do pathologists test for HER2-ultralow status for Enhertu?

> “Perform HER2 IHC testing to identify patients 
> with HER2-ultralow mBC who may be eligible 
> for HER2-directed treatment”

Source: [ENHERTU: ppusenb4673-enhertu-dx-branded-summary-brochure-digital--db09-update.pdf, page 2, captured 2026-11-13](https://www.enhertuhcp.com/-/media/pantumor_hcp/files/ppusenb4673-enhertu-dx-branded-summary-brochure-digital--db09-update.pdf?rev=0a563de806ba4ff1af577f1fa68c9ccf&hash=A40124C50237CA82F06FBA73320C9B20#page=2)

> “Any staining of the 
> membrane in >0 and ≤10% 
> of the cancer cells<sup>a-c</sup>”

Source: [ENHERTU: ppusenb4673-enhertu-dx-branded-summary-brochure-digital--db09-update.pdf, page 2, captured 2026-11-13](https://www.enhertuhcp.com/-/media/pantumor_hcp/files/ppusenb4673-enhertu-dx-branded-summary-brochure-digital--db09-update.pdf?rev=0a563de806ba4ff1af577f1fa68c9ccf&hash=A40124C50237CA82F06FBA73320C9B20#page=2)

> “Test for HER2-ultralow with IHC using the proposed scoring algorithm based on 
> the PATHWAY HER2 (4B5) FDA-authorized companion diagnostic scoring criteria for 
> breast cancer<sup>1,2,7</sup>”

Source: [ENHERTU: ppusenb4673-enhertu-dx-branded-summary-brochure-digital--db09-update.pdf, page 2, captured 2026-11-13](https://www.enhertuhcp.com/-/media/pantumor_hcp/files/ppusenb4673-enhertu-dx-branded-summary-brochure-digital--db09-update.pdf?rev=0a563de806ba4ff1af577f1fa68c9ccf&hash=A40124C50237CA82F06FBA73320C9B20#page=2)

> “<sup>a</sup>Review at 40x is recommended to discern the presence or absence of any staining such as faint, partial staining.<sup>2</sup>
> <sup>b</sup>Recommend re-reading by a second pathologist for cases classified as HER2-null or as HER2-ultralow expression with % of tumor cells ≤5%.<sup>2</sup>
> <sup>c</sup>In the HER2-ultralow “IHC 0 with membrane staining” category, partial membranous staining is usually faint but may exhibit stronger 
> intensities, and such rare cases are scored as HER2-ultralow if they do not otherwise qualify for a higher score. Refer to the PATHWAY 
> HER2 (4B5) Interpretation Guide for case examples.<sup>2</sup>”

Source: [ENHERTU: ppusenb4673-enhertu-dx-branded-summary-brochure-digital--db09-update.pdf, page 2, captured 2026-11-13](https://www.enhertuhcp.com/-/media/pantumor_hcp/files/ppusenb4673-enhertu-dx-branded-summary-brochure-digital--db09-update.pdf?rev=0a563de806ba4ff1af577f1fa68c9ccf&hash=A40124C50237CA82F06FBA73320C9B20#page=2)

<a id="enhertu-her2-low-ultralow-prevalence"></a>

### How common is HER2-ultralow breast cancer (Enhertu DESTINY-Breast06 screening)?

> “As demonstrated in DESTINY-Breast06 screening data. Among the 1856 patients screened for participation in the study, 12% (225 patients) had IHC 0 with absent membrane staining, while 22% (402 patients) were classified as HER2-ultralow, defined as IHC 0 with membrane staining. IHC 1+ was observed in 45% (829 patients), and IHC 2+/ISH– in 21% (385 patients).”

Source: [ENHERTU: About HER2-low and HER2-ultralow Metastatic Breast Cancer, captured 2026-11-13](https://www.enhertuhcp.com/en/her2-low-her2-ultralow-breast/about-her2-low-her2-ultralow-mbc#:~:text=As%20demonstrated%20in%20DESTINY%2DBreast06%20screening,2%2B%2FISH%E2%80%93%20in%2021%25%20%28385%20patients%29.)

Note: Proportions among 1856 patients with HR-positive, HER2-negative metastatic breast cancer screened for DESTINY-Breast06.

## Related pages
- [Medical information: Enhertu (fam-trastuzumab deruxtecan-nxki): HR-positive HER2-low or HER2-ultralow breast cancer](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer)
- [Clinical trials](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/enhertu--hr-positive-her2-low-or-her2-ultralow-breast-cancer/guidelines)
